Next Article in Journal
Germinal Centre B Cell Functions and Lymphomagenesis: Circuits Involving MYC and MicroRNAs
Next Article in Special Issue
Hypoxia and EGF Stimulation Regulate VEGF Expression in Human Glioblastoma Multiforme (GBM) Cells by Differential Regulation of the PI3K/Rho-GTPase and MAPK Pathways
Previous Article in Journal
Laquinimod Supports Remyelination in Non-Supportive Environments
Previous Article in Special Issue
Adenosine Depletion as A New Strategy to Decrease Glioblastoma Stem-Like Cells Aggressiveness
Open AccessReview

Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-Angiotensin System

1
Department of Neurosurgery, Wellington Regional Hospital, Wellington 6021, New Zealand
2
Gillies McIndoe Research Institute, Wellington 6021, New Zealand
3
Department of Surgery, The University of Melbourne, Parkville, VIC 3050, Australia
4
Department of Neurosurgery, Hadassah Hebrew University Medical Centre, Jerusalem 91120, Israel
5
Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia
6
Wellington Regional Plastic, Maxillofacial & Burns Unit, Hutt Hospital, Lower Hutt 5040, New Zealand
*
Author to whom correspondence should be addressed.
Cells 2019, 8(11), 1364; https://doi.org/10.3390/cells8111364
Received: 27 September 2019 / Revised: 23 October 2019 / Accepted: 29 October 2019 / Published: 31 October 2019
Patients with glioblastoma (GB), a highly aggressive brain tumor, have a median survival of 14.6 months following neurosurgical resection and adjuvant chemoradiotherapy. Quiescent GB cancer stem cells (CSCs) invariably cause local recurrence. These GB CSCs can be identified by embryonic stem cell markers, express components of the renin-angiotensin system (RAS) and are associated with circulating CSCs. Despite the presence of circulating CSCs, GB patients rarely develop distant metastasis outside the central nervous system. This paper reviews the current literature on GB growth inhibition in relation to CSCs, circulating CSCs, the RAS and the novel therapeutic approach by repurposing drugs that target the RAS to improve overall symptom-free survival and maintain quality of life. View Full-Text
Keywords: glioblastoma; renin-angiotensin system; cancer stem cells; drug repurposing glioblastoma; renin-angiotensin system; cancer stem cells; drug repurposing
Show Figures

Figure 1

MDPI and ACS Style

Tan, D.C.H.; Roth, I.M.; Wickremesekera, A.C.; Davis, P.F.; Kaye, A.H.; Mantamadiotis, T.; Stylli, S.S.; Tan, S.T. Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-Angiotensin System. Cells 2019, 8, 1364.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop